July 13, 2016 | Israeli molecular diagnostic company ImmunArray has closed a Series B financing round of $10 million led by private investment firm Exigent. With offices in Rehovot, Israel and Richmond, Virginia, ImmunArray has developed novel blood tests and pioneers new and more accurate ways to diagnose autoimmune diseases such as lupus as well as traumatic brain injury (TBI). The company was founded in 2006 based on iCHIP technology licensed from the Weizmann Institute of Science. iCHIP technology can determine the presence of a specific set of molecular biomarkers that are linked to particular disease or condition.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments